# Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

> **NCT05961124** · PHASE2 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 40 (estimated)

## Conditions studied

- Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- High Grade Ovarian Serous Adenocarcinoma

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05961124
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-21
- **Primary completion:** 2025-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05961124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05961124, "Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05961124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*